The role of radiation therapy in the treatment of metastatic castrate-resistant prostate cancer
This article focuses on these options, including both external beam radiotherapy and radiopharmaceuticals. (Source: Therapeutic Advances in Urology)
Source: Therapeutic Advances in Urology - May 25, 2015 Category: Urology & Nephrology Authors: Rose, J. N., Crook, J. M. Tags: Reviews Source Type: research
Efficacy of triptorelin pamoate 11.25 mg administered subcutaneously for achieving medical castration levels of testosterone in patients with locally advanced or metastatic prostate cancer
Conclusions:
This study demonstrates that triptorelin pamoate 11.25 mg administered by the subcutaneous route every 3 months is as efficacious and well tolerated as administration via the intramuscular route in men with locally advanced or metastatic prostate cancer. (Source: Therapeutic Advances in Urology)
Source: Therapeutic Advances in Urology - May 25, 2015 Category: Urology & Nephrology Authors: Lebret, T., Rouanne, M., Hublarov, O., Jinga, V., Petkova, L., Kotsev, R., Sinescu, I., Dutailly, P. Tags: Original Research Source Type: research
A prospective, observational grouped analysis to evaluate the effect of triptorelin on lower urinary tract symptoms in patients with advanced prostate cancer
Conclusions:
The improvement in LUTS in men with locally advanced or metastatic prostate cancer after 24–48 weeks suggests that triptorelin is effective in improving LUTS in this subgroup of patients. (Source: Therapeutic Advances in Urology)
Source: Therapeutic Advances in Urology - May 25, 2015 Category: Urology & Nephrology Authors: Gil, T., Aoun, F., Cabri, P., Maisonobe, P., van Velthoven, R. Tags: Original Research Source Type: research
Efficacy of degarelix in prostate cancer patients following failure on luteinizing hormone-releasing hormone agonist treatment: results from an open-label, multicentre, uncontrolled, phase II trial (CS27)
Conclusions:
In PCa patients who failed LHRH therapy, degarelix was well tolerated and achieved a limited PSA response. Phase III trials show that disease control benefits with degarelix versus agonists are more clearly demonstrated as first-line therapy. (Source: Therapeutic Advances in Urology)
Source: Therapeutic Advances in Urology - May 25, 2015 Category: Urology & Nephrology Authors: Miller, K., Simson, G., Goble, S., Persson, B.-E. Tags: Original Research Source Type: research
Management of idiopathic retroperitoneal fibrosis from the urologist's perspective
Conclusions:
The imaging procedures available today are unable to accurately differentiate between idiopathic and malignant RF. A biopsy is mandatory to confirm the diagnosis, but there is no consensus regarding the template, timing and number of biopsies needed to exclude malignancy. Open ureterolysis represents the main surgical treatment for cases with severe IRF, and laparoscopic or robotic approach may be an option in selected cases. The recovery of the renal function is a surrogate for evaluating the success of the treatment. More clinical studies are needed in order standardize the protocol for diagnostic, treatment...
Source: Therapeutic Advances in Urology - March 24, 2015 Category: Urology & Nephrology Authors: Cristian, S., Cristian, M., Cristian, P., Constantin, G., Savu, C., Huri, E., Sinescu, I. Tags: Review Source Type: research
The double urethra: revisiting the surgical classification
Conclusion:
The double urethra is a diverse spectrum comprising different pathologies. Our proposed classification system of duplicated urethras is clinically relevant as it guides surgical management and allows prognostication of outcome. (Source: Therapeutic Advances in Urology)
Source: Therapeutic Advances in Urology - March 24, 2015 Category: Urology & Nephrology Authors: AbouZeid, A. A., Safoury, H. S., Mohammad, S. A., El-Naggar, O., Zaki, A. M., Hassan, T. A., Hay, S. A. Tags: Original Research Source Type: research
A report of a regional service for post-prostatectomy urinary incontinence: a model for best practice?
Conclusion:
PPI is of increasing personal and societal impact which should be identified early and supported. Investigation and management can be standardized and intervention at a high volume centre achieved by early specialist referral. (Source: Therapeutic Advances in Urology)
Source: Therapeutic Advances in Urology - March 24, 2015 Category: Urology & Nephrology Authors: Almallah, Y. Z., Grimsley, S. J. S. Tags: Original Research Source Type: research
Sites of disease as predictors of outcome in metastatic renal cell carcinoma patients treated with first-line sunitinib or sorafenib
Conclusions:
mRCC patients with liver metastases treated with first-line SO showed a better outcome compared with SU, while mRCC patients without liver metastases treated with first-line SU showed a better outcome compared with SO. (Source: Therapeutic Advances in Urology)
Source: Therapeutic Advances in Urology - March 24, 2015 Category: Urology & Nephrology Authors: Grassi, P., Verzoni, E., Porcu, L., Iacovelli, R., de Braud, F., Procopio, G. Tags: Original Research Source Type: research
Desmoid tumor: an unusual case of gross hematuria
In this report, we present a case of desmoid tumor presenting with gross hematuria. (Source: Therapeutic Advances in Urology)
Source: Therapeutic Advances in Urology - January 13, 2015 Category: Urology & Nephrology Authors: Isharwal, S., Desai, V., Horn, A., Lele, S. M., Lagrange, C. A. Tags: Letter to the Editor Source Type: research
Avoiding and managing vascular injury during robotic-assisted radical prostatectomy
We present the most common vascular injuries in robot-assisted radical prostatectomy, as well as their management and prevention. We believe that it is of vital importance to be able to recognize these injuries so that they can be prevented. (Source: Therapeutic Advances in Urology)
Source: Therapeutic Advances in Urology - January 13, 2015 Category: Urology & Nephrology Authors: Sotelo, R., Nunez Bragayrac, L. A., Machuca, V., Garza Cortes, R., Azhar, R. A. Tags: Reviews Source Type: research
The potential role of stem cells in the treatment of urinary incontinence
Voiding dysfunction encompasses a wide range of urologic disorders including stress urinary incontinence and overactive bladder that have a detrimental impact on the quality of life of millions of men and women worldwide. In recent years, we have greatly expanded our understanding of the pathophysiology of these clinical conditions. However, current gold standard therapies often provide symptomatic relief without targeting the underlying etiology of disease development. Recently, the use of stem cells to halt disease progression and reverse underlying pathology has emerged as a promising method to restore normal voiding fu...
Source: Therapeutic Advances in Urology - January 13, 2015 Category: Urology & Nephrology Authors: Tran, C., Damaser, M. S. Tags: Reviews Source Type: research
An update on enzalutamide in the treatment of prostate cancer
Enzalutamide is an oral androgen receptor inhibitor that targets multiple steps in the androgen receptor signaling pathway. In the randomized phase III AFFIRM study, significant improvements in survival versus placebo were observed when enzalutamide was used as a treatment for patients with metastatic castration-resistant prostate cancer (mCRPC) following prior treatment with docetaxel. Additional benefits included significant delay in time to first skeletal-related event, and improvement in several measures of pain and health-related quality of life. Treatment effects were consistent across all prespecified subgroups. The...
Source: Therapeutic Advances in Urology - January 13, 2015 Category: Urology & Nephrology Authors: Merseburger, A. S., Haas, G. P., von Klot, C.-A. Tags: Reviews Source Type: research
A prospective, randomized comparative study of monopolar transurethral resection of the prostate versus photoselective vaporization of the prostate with GreenLight 120-W laser, in prostates less than 80 cc
Conclusion:
Prostate PVP and TURP are effective surgical treatments for benign prostatic hyperplasia. Postoperative functional improvements were durable and equivalent in the two groups. The two techniques have a similar complication rate. (Source: Therapeutic Advances in Urology)
Source: Therapeutic Advances in Urology - January 13, 2015 Category: Urology & Nephrology Authors: Telli, O., Okutucu, T. M., Suer, E., Burgu, B., Gulpinar, O., Yaman, O., Bozkurt, S. Tags: Original Research Source Type: research
Potential utility of cancer-specific biomarkers for assessing response to hormonal treatments in metastatic prostate cancer
Prostate cancer is the second leading cause of cancer death in men and there is an urgent clinical need to improve its detection and treatment. The introduction of prostate-specific antigen (PSA) as a biomarker for prostate cancer several decades ago represented an important step forward in our ability to diagnose this disease and offers the potential for earlier and more effective treatment. PSA measurements are now routinely conducted alongside digital rectal examination, with raised PSA levels leading to biopsy. PSA is also used to monitor disease and assess therapeutic response. However, there are some important limita...
Source: Therapeutic Advances in Urology - November 18, 2014 Category: Urology & Nephrology Authors: Schalken, J., Dijkstra, S., Baskin-Bey, E., van Oort, I. Tags: Reviews Source Type: research
Management of priapism: an update for clinicians
Priapism is a prolonged erection that persists beyond or is unrelated to sexual stimulation. It is associated with significant morbidity: psychological, socioeconomic, and physical, including pain and potentially irreversible compromise of erectile function. There are three major types of priapism: ischemic, nonischemic, and stuttering. Establishing the type of priapism is paramount to safely and effectively treating these episodes. Ischemic priapism represents a urological emergency. Its treatment may involve aspiration/irrigation with sympathomimetic injections, surgical shunts, and as a last resort, penile prosthesis im...
Source: Therapeutic Advances in Urology - November 18, 2014 Category: Urology & Nephrology Authors: Levey, H. R., Segal, R. L., Bivalacqua, T. J. Tags: Reviews Source Type: research
